• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preventing respiratory syncytial virus in infants.

作者信息

Moe Samantha S, Wong Sam, Kolber Michael R

机构信息

Clinical Evidence Expert at the College of Family Physicians of Canada.

Associate Clinical Professor in the Department of Pediatrics at the University of Alberta in Edmonton.

出版信息

Can Fam Physician. 2024 Oct;70(10):e155. doi: 10.46747/cfp.7010e155.

DOI:10.46747/cfp.7010e155
PMID:39406437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11477242/
Abstract
摘要

相似文献

1
Preventing respiratory syncytial virus in infants.预防婴儿呼吸道合胞病毒感染
Can Fam Physician. 2024 Oct;70(10):e155. doi: 10.46747/cfp.7010e155.
2
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.对高危婴幼儿预防性给予呼吸道合胞病毒免疫球蛋白。呼吸道合胞病毒免疫球蛋白研究组。
N Engl J Med. 1993 Nov 18;329(21):1524-30. doi: 10.1056/NEJM199311183292102.
3
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.使用帕利珠单抗（一种人源化呼吸道合胞病毒单克隆抗体）进行免疫预防以预防高危婴儿呼吸道合胞病毒感染：共识意见。
Pediatr Infect Dis J. 1999 Mar;18(3):223-31. doi: 10.1097/00006454-199903000-00004.
4
Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin.高危婴儿呼吸道合胞病毒感染的预防：关于呼吸道合胞病毒高效价免疫球蛋白免疫预防作用的共识意见
Pediatr Infect Dis J. 1996 Dec;15(12):1059-68. doi: 10.1097/00006454-199612000-00001.
5
Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.高危婴儿呼吸道合胞病毒的预防：免疫球蛋白的应用及感染的流行病学监测
Tex Med. 2000 May;96(5):58-61.
6
Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada.在加拿大，尼塞韦单抗和母体呼吸道合胞病毒前融合蛋白疫苗用于预防婴儿呼吸道合胞病毒疾病的成本效益。
BMC Med. 2025 Feb 21;23(1):102. doi: 10.1186/s12916-025-03928-z.
7
Maternal vaccination: a promising preventive strategy to protect infants from respiratory syncytial virus.母体疫苗接种：一种保护婴儿免受呼吸道合胞病毒感染的有前景的预防策略。
Hong Kong Med J. 2024 Aug;30(4):264-267. doi: 10.12809/hkmj245157. Epub 2024 Jul 8.
8
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.哥伦比亚早产儿和婴儿使用帕利珠单抗预防呼吸道合胞病毒的成本-效用分析。
BMC Infect Dis. 2024 Apr 19;24(1):418. doi: 10.1186/s12879-024-09300-5.
9
Prophylaxis against respiratory syncytial virus in premature infants.早产儿呼吸道合胞病毒的预防
Lancet. 2000 Jan 15;355(9199):235-6. doi: 10.1016/S0140-6736(05)72113-9.
10
Access to respiratory syncytial virus preventive tools for neonates and infants in Europe.
Lancet Infect Dis. 2024 Apr;24(4):343-345. doi: 10.1016/S1473-3099(24)00084-7. Epub 2024 Feb 19.

本文引用的文献

1
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.尼赛珠单抗预防婴儿呼吸道合胞病毒住院治疗。
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
2
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.儿科呼吸道合胞病毒相关住院治疗在 COVID-19 大流行之前和期间。
JAMA Netw Open. 2023 Oct 2;6(10):e2336863. doi: 10.1001/jamanetworkopen.2023.36863.
3
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.《使用尼赛珠单抗预防婴幼儿呼吸道合胞病毒疾病：免疫实践咨询委员会的建议-美国，2023 年》。
MMWR Morb Mortal Wkly Rep. 2023 Aug 25;72(34):920-925. doi: 10.15585/mmwr.mm7234a4.
4
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.Nirsevimab用于预防足月儿和晚期早产儿的呼吸道合胞病毒感染
N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5.
5
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.尼塞维单抗用于患有心脏或肺部疾病或早产的婴儿预防呼吸道合胞病毒感染的安全性
N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186.
6
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.尼赛珠单抗预防健康晚期早产儿和足月婴儿 RSV 感染。
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
7
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.帕利珠单抗预防儿童严重呼吸道合胞病毒（RSV）感染。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2.
8
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.尼氏司他单抗单剂预防早产儿 RSV 感染。
N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.
9
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.帕利珠单抗预防可降低患有血流动力学显著先天性心脏病的幼儿因呼吸道合胞病毒感染导致的住院率。
J Pediatr. 2003 Oct;143(4):532-40. doi: 10.1067/s0022-3476(03)00454-2.
10
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.帕利珠单抗是一种人源化呼吸道合胞病毒单克隆抗体，可降低高危婴儿因呼吸道合胞病毒感染而住院的几率。IMpact-RSV研究小组。
Pediatrics. 1998 Sep;102(3 Pt 1):531-7.